About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTH™ or to request a representative, visit YCANTHPro.com
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
2023
Submit
February 27, 2023
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
February 21, 2023
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
January 24, 2023
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
January 4, 2023
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
< previous
1
2
3
4
5
